SCR-LIP-000147 · Claim · machine-readable JSON →
In lipedema patients, pain prevalence and von Frey cutaneous hypersensitivity increased with disease stage (60-100% leg pain across stages, painDETECT >19 only in Stage 3), with reduced dermal Tuj-1+ neuronal density in abdomen and elevated CGRP/NGF in Stage 3 tissues suggesting peripheral neuropathic pain and neurogenic inflammation, independent of BMI.
Claim at a glance
- Type
- clinical association
- Knowledge state
- Emerging
- Evidence certainty
- low (GRADE)
- Evidence
- 1 source(s)
- Answers
- 2 question(s)
- Dates
- 2026-05-31 → 2026-05-31
Structured evidence, machine-compiled — not a verdict.
Auto-compiled by the Layer 1 surveillance loop; not yet human-reviewed. anthropic/claude-opus-4.8 · 2026-05-31
Evidence over time
Evidence (1)
- Indications of Peripheral Pain, Dermal Hypersensitivity, and Neurogenic Inflammation in Patients with Lipedema — Chakraborty et al. (2022) ✓ verified — refining · cross sectional · 2022 · reading confidence: high
“painDETECT cumulativo: 11,0±5,2 (S1) vs 10,5±4,9 (S2) vs 17,6±7,2 (S3); p=0,0271; apenas Stage 3 apresentou respondedores >19 (dor neuropática)”
The article characterizes pain mechanisms (peripheral neuropathic pain, dermal hypersensitivity, neurogenic inflammation) within lipedema across stages, supporting lipedema as a chronic-pain condition, but it does not examine fibromyalgia o
Context (PECO)
Answers these questions
- Is lipedema associated with fibromyalgia and other chronic-pain conditions? refining
- What is known about the inflammation and pain mechanism in lipedema tissue? consistent
Gaps & caveats
Auto-ingested single source; not yet human-reviewed.
Change log
- 2026-06-02 — merged · absorbed duplicate SCR-LIP-000090
- 2026-05-31 — created